Cargando…

PRMT6 increases cytoplasmic localization of p21(CDKN1A) in cancer cells through arginine methylation and makes more resistant to cytotoxic agents

p21(CDKN1A) is known as a potent inhibitor of cyclin-dependent kinase (CDK), which regulates cell cycle in response to various stimuli, including DNA damage, on the p53-dependent manner. Here we demonstrate that protein arginine methyltransferase 6 (PRMT6) methylates p21 at arginine 156 and promotes...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakakido, Makoto, Deng, Zhenzhong, Suzuki, Takehiro, Dohmae, Naoshi, Nakamura, Yusuke, Hamamoto, Ryuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741580/
https://www.ncbi.nlm.nih.gov/pubmed/26436589
Descripción
Sumario:p21(CDKN1A) is known as a potent inhibitor of cyclin-dependent kinase (CDK), which regulates cell cycle in response to various stimuli, including DNA damage, on the p53-dependent manner. Here we demonstrate that protein arginine methyltransferase 6 (PRMT6) methylates p21 at arginine 156 and promotes phosphorylation of threonine 145 on p21, resulting in the increase of cytoplasmic localization of p21. The cytoplasmic presence of p21 makes cancer cells more resistant to cytotoxic agents. Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.